ClinicalTrials.gg
CompletedNCT01742637Updated May 4, 2017

Study Comparing Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% to Epiduo® and Both to a Placebo Control in the Treatment of Acne Vulgaris

A Phase 1 interventional study of Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% and Epiduo® Gel in Acne Vulgaris, sponsored by Taro Pharmaceuticals USA. Completed. Open to participants aged 12 Years to 40 Years. Per ClinicalTrials.gov, last updated 2017-05-04.

Sponsored by Taro Pharmaceuticals USA (part of Sun Pharmaceutical Industries Limited) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
2,008
Allocation
Randomized
Ages
12 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies in Acne Vulgaris by Sun Pharmaceutical Industries Limited — none open to participants now, 1 under way, none of them phase 3. Acne Vulgaris · Sun Pharmaceutical Industries Limited.

Enrollment
Largest of 30
2,008 · median 727
Started
2012
with 2 others
Phase 1
21 of 30
none open now
Registered
3rd of 30
by date

Among the 30 studies in Acne Vulgaris by Sun Pharmaceutical Industries Limited, this one has the largest enrollment, is one of 3 that started in 2012, is one of 21 in phase 1, and was the 3rd registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

None of the 30 studies in Acne Vulgaris by Sun Pharmaceutical Industries Limited is open now. The open studies under Acne Vulgaris, anywhere →

Where they have run

Who these studies take

Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 12 Years to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 30 studies in Acne Vulgaris by Sun Pharmaceutical Industries Limited as a file.
02

Study summary

The objective of this study is to evaluate the therapeutic equivalence and safety of Adapalene and Benzoyl Peroxide 0.1%/2.5% Gel (Taro Pharmaceuticals Inc.) and Epiduo® (Adapalene and Benzoyl Peroxide 0.1%/2.5% Gel) (Galderma Laboratories, L.P.) in the treatment of acne vulgaris, and to demonstrate the superiority of the efficacy of the test and reference products over the vehicle (placebo) control in the treatment of acne vulgaris.

03

Conditions studied

  • Acne Vulgaris

Browse trials for

Keywords

  • Acne Vulgaris
  • Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%
  • Epiduo®
04

Who can participate

Ages eligible
12 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male or non pregnant female aged ≥ 12 and ≤ 40 years with a clinical diagnosis of acne vulgaris.
  • Subjects who are 18 years of age or older must have provided written . Subjects 12 to 17 years of age must have provided written assent, which must be accompanied by written informed consent from the subject's legally acceptable representative. All subjects or their legally acceptable representatives must sign a Health Insurance Portability and Accountability Act authorization.
  • Subjects must have a minimum of ≥ 25 non-inflammatory lesions and ≥ 20 inflammatory lesions and ≤ 2 nodulocystic lesions, at baseline on the face.
  • Subjects must have a definite clinical diagnosis of acne vulgaris severity grade 2, 3, or 4 as per the Investigator's Global Assessment (IGA).
  • Subjects must be willing to refrain from using all other topical acne medications or antibiotics for acne vulgaris during the 12-week treatment period, other than the product.
  • Female subjects of (excluding those who are surgically sterilized or for at least 1 year), in addition to having a negative urine pregnancy test, must be willing to use an acceptable form of during the study from the day of the first dose administration to 30 days after the last administration of study drug.
  • All male subjects must agree to use accepted methods of birth control with their partners, from the day of the first dose administration to 30 days after the last administration of study drug.
  • Subjects must be willing and able to understand and comply with the requirements of the protocol.
  • Subjects must be in good health and free from any disease, including but not limited to, conditions that may interfere with the evaluation of acne vulgaris.
  • Subjects who use make-up must have used the same brands/types for a minimum period of 14 days prior to study entry and must agree to not change brand/type or frequency of use throughout the study.

Exclusion criteria

Exclusion Criteria:

  • Female subjects who are pregnant, nursing or planning to become pregnant during study participation.
  • Subjects with a history of or allergy to adapalene, retinoids and/or any of the study medication ingredients, have a known hypersensitivity to adapalene and benzoyl peroxide and its .
  • Subjects with the presence of any skin condition that would interfere with the diagnosis or assessment of acne vulgaris.
  • Subjects with excessive facial hair that would interfere with diagnosis or assessment of acne vulgaris.
  • Subjects who have performed wax depilation of the face within 14 days prior to baseline.
  • Subjects who have used within 6 months prior to baseline or use during the study of oral retinoids or therapeutic Vitamin A supplements of greater than 10,000 units/day.
  • Subjects who have used estrogens or oral for less than 3 months prior to baseline.
  • Subjects who have used any of the following procedures on the face within 1 month prior to baseline or use during the study: cryodestruction or chemodestruction, dermabrasion, photodynamic therapy, acne surgery, intralesional , x-ray therapy.
  • Subjects who have used any of the following treatments within 1 month prior to baseline or use during the study: systemic steroids, systemic antibiotics, systemic treatment for acne vulgaris, systemic anti-inflammatory agents.
  • Subjects who have used any of the following treatments within 2 weeks prior to baseline or during the study: topical steroids, topical retinoids, α-hydroxy/glycolic acid, benzoyl peroxide, topical anti-inflammatory agents, topical antibiotics.
  • Use of spironolactone is prohibited during the study.
  • Use of tanning booths, sunbathing, or excessive exposure to the sun are prohibited during the study.
  • Subjects who have received radiation therapy and/or anti-neoplastic agents within 90 days prior to baseline.
  • Subjects who have unstable medical disorders that are or have life-threatening diseases.
  • Subjects who have on-going requiring systemic treatment, and subjects who have any malignancy of the skin of the facial area.
  • Subjects who engage in activities that involve excessive or prolonged exposure to sunlight or weather extremes, such as wind or cold.
  • Subjects who consume excessive amounts of alcohol or use drugs of abuse.
  • Subjects who have participated in an drug study within 30 days prior to baseline.
  • Subjects who have been previously enrolled in this study.
  • Subjects who have had laser therapy, electrodesiccation and phototherapy to the facial area within 180 days prior to study entry.
  • Subjects who have had cosmetic procedures which may affect the efficacy and safety profile of the investigational product within 14 days prior to study entry. Cosmetic procedures and facials are prohibited throughout the study.
  • Subjects who currently have or have recently had bacterial folliculitis on the face.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
2,008 participants (actual)

Study arms

  • Experimental
    Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%

    Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% (Taro Pharmaceuticals Inc.)

    Drug: Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%

  • Active comparator
    Epiduo® Gel

    Epiduo® (Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%) (Galderma Laboratories, L.P.)

    Drug: Epiduo® Gel

  • Placebo comparator
    Placebo

    Placebo (vehicle of test product) (Taro Pharmaceuticals Inc.)

    Drug: Placebo

Interventions

  • DrugAdapalene and Benzoyl Peroxide Gel 0.1%/2.5%

    Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% (Taro Pharmaceuticals Inc.)applied topically once daily for 84 consecutive days.

  • DrugEpiduo® Gel

    Epiduo® (Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%) (Galderma Laboratories, L.P.)applied topically once daily for 84 consecutive days.

  • DrugPlacebo

    Placebo (vehicle of test product) (Taro Pharmaceuticals Inc.)applied topically once daily for 84 consecutive days.

06

What researchers measure

Primary outcomes

  1. Inflammatory and non-inflammatory lesion counts

    Percent change from baseline to week 12 in the inflammatory (papules and pustules) and non-inflammatory (open and closed comedones) lesion counts.

    Time frame: Week 12

Secondary outcomes

  1. Clinical response of success.

    The proportion of subjects with a clinical response (IGA) of success at week 12. Success should be defined as an IGA score that is at least 2 grades less than the baseline assessment.

    Time frame: Week 12

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2012, a primary completion of Feb 2014 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2012
First posted
Dec 5, 2012
Start
Oct 2012
Primary completionActual
Feb 2014
CompletionActual
Mar 2014
Last update
May 4, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01742637
Responsible party
Sponsor
First posted
Dec 5, 2012
Start date
Oct 2012
Primary completion
Feb 2014
Completion
Mar 2014
Last update
May 4, 2017

Study contacts

Catawba Research
study chair · http://catawbaresearch.com/contact/

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion